Repare Therapeutics shares surged over 21% premarket. This is after Gilead Sciences agreed to acquire its investigational cancer drug RP-3467 for up to $30 million. The deal includes $25 million upfront and $5 million tied to technology transfer milestones. This will be boosting bullish retail sentiment around the stock.